Valuation: IN8bio, Inc.

Market Cap 12.41M 10.88M 10.05M 9.25M 17.44M 1.2B 17.72M 120M 47.12M 585M 46.59M 45.57M 2.02B P/E 2026 *
-1.01x
P/E 2027 * -1.19x
Enterprise Value 12.41M 10.88M 10.05M 9.25M 17.44M 1.2B 17.72M 120M 47.12M 585M 46.59M 45.57M 2.02B EV / Sales 2026 *
-
EV / Sales 2027 * 15x
Free-Float
86.6%
Yield 2026 *
-
Yield 2027 * -
1 day-5.26%
1 week-5.97%
Current month-10.64%
1 month-11.89%
3 months-16.00%
6 months-46.61%
Current year-46.15%
1 week 1.23
Extreme 1.23
1.46
1 month 1.23
Extreme 1.23
1.53
Current year 1.23
Extreme 1.23
2.73
1 year 1.17
Extreme 1.17
2.73
3 years 1.17
Extreme 1.17
74.4
5 years 1.17
Extreme 1.17
309.57
10 years 1.17
Extreme 1.17
309.57
Manager TitleAgeSince
Chief Executive Officer 50 2015-10-31
Chief Tech/Sci/R&D Officer 72 2018-10-31
Director of Finance/CFO 43 2021-02-07
Director TitleAgeSince
Director/Board Member 50 2015-10-31
Director/Board Member 68 2019-06-30
Director/Board Member 64 2021-08-03
Date Insider Type Main position Quantity % Market Cap.
5/27/26 Don

Director

-724,637 7.3589%
5/9/26 Free

Director

22,000 0.2234%
5/9/26 Free

Chief Financial Officer

56,250 0.5712%
Change 5-day change 1-year change 3-year change Capi.($)
-5.26%-5.97%-41.94%-97.38% 12.41M
+0.21%-0.79%+53.17%+57.39% 53.79B
+5.37%+3.31%+50.39%+83.65% 54.69B
-1.20%-1.94%+4.35%+402.68% 23.2B
+0.74%+2.32%-16.23%-14.44% 23.31B
+0.21%+0.37%+36.93%-5.80% 20.03B
-1.18%-2.97%+30.12%-33.30% 17.31B
-1.67%-6.00%+163.95%+284.69% 14.99B
-0.83%+0.32%+32.36%+570.87% 15.36B
-0.70%-0.91%+24.87%+179.47% 13.96B
Average -0.43%-1.24%+33.80%+142.78% 23.66B
Weighted average by Cap. +0.97%-0.93%+41.84%+133.19%

Financials

2026 *2027 *
Net sales - 830K 727K 672K 618K 1.17M 80.01M 1.19M 8.04M 3.15M 39.15M 3.12M 3.05M 135M
Net income -22.29M -19.54M -18.06M -16.61M -31.34M -2.15B -31.85M -216M -84.66M -1.05B -83.71M -81.89M -3.62B -25.76M -22.58M -20.87M -19.2M -36.22M -2.48B -36.8M -250M -97.84M -1.22B -96.74M -94.63M -4.19B
Net Debt - -
Logo IN8bio, Inc.
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors.
Employees
18
Date Price Change Volume
26-07-20 US$1.260 -5.26% 54,599
26-07-17 US$1.330 -3.62% 65,504
26-07-16 US$1.380 -4.17% 105,006
26-07-15 US$1.440 +4.35% 75,314
26-07-14 US$1.380 +2.99% 16,249
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.260USD
Average target price
6.250USD
Spread / Average Target
+396.03%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INAB Stock